postmenopausal osteopenia
Conditions
Interventions
Control group:placebo-moxibustion treatment
Experimental group:moxibustion treatment
Sponsors
West China Hospital, Sichuan University
Eligibility
Sex/Gender
Female
Age
40 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. In line with the 'Guidelines for the Diagnosis and Treatment of Primary Osteoporosis (2017)' formulated by the Osteoporosis and Bone Mineral Disease Branch of the Chinese Medical Association and issued by the American Academy of Clinical Endocrinologists (AACE) and the American College of Endocrinology (ACE) in 2016 'Low bone mass' diagnosis in 'Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis-2016'; 2. Aged 40 to 55 years, female; 3. Stop menstruation within 5 years; 4. The fracture risk assessment tool (FRAX) predicts a hip fracture probability < 3% and any major osteoporotic fracture probability < 20%; 5. Sign the informed consent and voluntarily participate in this experiment.
Exclusion criteria
Exclusion criteria: 1. Osteoporotic fractures have occurred; 2. Have used or are using anti-osteoporosis drugs (such as bisphosphonates, calcitonin, etc.); 3. Taking other drugs that affect bone metabolism (such as estrogen, glucocorticoid, etc.) in the past 3 months; 4. Abnormal lumbar spine or hip anatomy, unable to accurately measure bone mineral density using DXA test; 5. Suffering from secondary osteoporosis-related endocrine diseases (such as diabetes, hyperthyroidism, hypothyroidism, thyroid cyst, etc.); 6. Suffering from rickets, rheumatoid arthritis and other diseases affecting bone metabolism balance; 7. Those with hysterectomy or oophorectomy; 8. Patients with severe heart, liver, kidney, mental illness, etc.; 9. Drug or alcohol dependence or abusers; 10. Patients participating in other clinical trials.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| BMD of the lumbar spine (L1-4); | — |
Secondary
| Measure | Time frame |
|---|---|
| lumbar bone density;hip bone density;Bone turnover markers ;visual analog score (VAS) of bone pain;assessment of health-related quality of life;incidence of osteoporosis or fractures;usage of emergency drug or surgery related to bone loss;the participants self-evaluation of therapeutic effects;serum calcium, magnesium, phosphorus, parathyroid hormone (PTH) and 25-hydroxyvitamin D levels; | — |
Countries
China
Contacts
Public ContactLu Lingyun
West China Hospital, Sichuan University
Outcome results
None listed